atorvastatin has been researched along with Fibrosis in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (16.67) | 29.6817 |
| 2010's | 33 (68.75) | 24.3611 |
| 2020's | 7 (14.58) | 2.80 |
| Authors | Studies |
|---|---|
| Mazumder, N; Parikh, ND; Tapper, EB; Zhao, Z | 1 |
| Ghazi-Khansari, M; Jazaeri, F; Mehreen, S; Niaz, Q; Tavangar, SM | 1 |
| Al Gharram, T; Mayyas, F | 1 |
| Chen, H; Chen, Z; Guo, J; Liu, H; Ma, Y; Peng, X; Wang, Q; Zheng, Z; Zhu, J | 1 |
| Duan, Q; Peng, X; Wang, J; Wang, Z; Xia, F | 1 |
| Baranowski, A; Förster, K; Hofmann, A; Klein, A; Mattyasovszky, SG; Mickan, T; Ritz, U; Rommens, PM; Schlemmer, L; Slotina, E; Truffel, S | 1 |
| Nie, W; Shi, K; Xie, D; Yu, B; Yu, M; Zhang, H | 1 |
| Cui, J; Grau, MS; Jaffer, FA; Jhajj, HS; Kessinger, CW; Libby, P; McCarthy, JR; Misra, S | 1 |
| Choi, SY; Kim, CR; Kim, MH; Park, JS; Roh, MS; Serebruany, V | 1 |
| Ghasemi, A; Hamzeh, M; Hosseinimehr, SJ; Naeimi, RA; Talebpour Amiri, F | 1 |
| Fernando, T; Kang, Q; Li, X; Wan, Z; Yang, M | 1 |
| Christenson, R; deFilippi, C; Fitch, KV; Grinspoon, SK; Hoffmann, U; Joyce, J; Lo, J; Looby, SE; Lu, MT; Park, EA; Wu, A | 1 |
| Chen, W; Gao, G; Ge, L; Jiang, S; Sui, S; Zhai, C; Zhang, S | 1 |
| Fang, T; Guo, B; Wang, L; Xue, L | 1 |
| Fukumoto, Y; Kudo, S; Liao, JK; Minami, T; Nochioka, K; Shiba, N; Shimokawa, H; Takai, Y; Tanaka, S; Williams, CL | 1 |
| Cao, S; Fang, W; He, Y; Li, R; Li, Y; Wang, J; Xi, S; Zhang, B | 1 |
| Dong, QT; Gao, RL; Geng, YJ; Gersh, BJ; He, ZX; Lu, MJ; Qian, HY; Qiao, SB; Shen, R; Song, L; Yang, YJ; Zhao, SH | 1 |
| An, Z; Dong, N; Ge, LL; He, YQ; Li, SM; Yang, G; Zhang, WQ | 1 |
| Akahori, H; Eguchi, A; Hirotani, S; Iwasaku, T; Masuyama, T; Matsumoto, M; Naito, Y; Sasaki, N; Sawada, H; Tsujino, T | 1 |
| Akdemir, A; Aktug, H; Erbas, O; Ergenoglu, M; Taskiran, D; Yavasoglu, A; Yildirim, N; Zeybek, B | 1 |
| Arévalo, M; Docherty, NG; Eleno, N; Fuentes-Calvo, I; Grande, MT; López-Novoa, JM; Pérez-Barriocanal, F; Rodríguez-Peña, AB | 1 |
| Cheng, WP; Lo, HM; Shyu, KG; Wang, BW | 1 |
| Harada, M; Otsuki, M; Wei, L; Yamamoto, M | 1 |
| Bonilla, H; Butt, AA; Chung, RT; Simon, TG; Yan, P | 1 |
| Chen, M; Li, H; Shen, X; Su, W; Wang, G; Zhao, S | 1 |
| Aguirre, A; Cho, YS; Fujimoto, JG; Jang, IK; Jia, H; Lee, H; Minami, Y; Soeda, T; Vergallo, R; Wang, Z; Xing, L; Yu, B | 1 |
| Chang, YY; Hung, CS; Kao, HL; Lee, JK; Lin, HJ; Lin, YH; Lin, YM; Lin, YT; Wu, YW | 1 |
| Carvalho Sposito, A; da Mota Silveira-Filho, L; de Souza Vilarinho, KA; Diógenes de Carvalho, D; Galluce Torina, A; Martins de Oliveira, PP; Pereira do Carmo, HR; Petrucci, O; Reichert, K | 1 |
| Dai, J; Hou, J; Hu, S; Jang, IK; Jia, H; Lee, H; Minami, Y; Ong, D; Soeda, T; Vergallo, R; Xing, L; Yu, B; Zhang, S | 1 |
| Carvajal-González, G; Egido, J; Mezzano, S; Ortiz, A; Rodrigues Díez, R; Rodrigues-Díez, R; Rodríguez-Vita, J; Ruiz-Ortega, M; Sánchez-López, E; Selgas, R | 1 |
| Clementi, F; Di Luozzo, M; Luciani, G; Mango, R; Martuscelli, E; Mehta, JL; Pizzuto, F; Romeo, F; Trivisonno, A | 1 |
| Boyle, A; Connelly, KA; Gilbert, RE; Kelly, D; Kompa, A; Krum, H; Martin, JH; Zhang, Y | 1 |
| Cui, W; Du, J; Han, M; Liu, DM; Liu, F; Lu, JC; Yin, HN; Zhang, HL; Zhang, K | 1 |
| Geng, J; Kang, W; Wang, W; Zhang, Y; Zhao, Z; Zhiming, GE | 1 |
| Chou, SY; Fitzgerald, JP; Franco, I; Gulmi, FA; Kim, H; Mooppan, UM; Saini, R | 1 |
| Civantos, E; Egido, J; Lavoz, C; Mezzano, S; Ortiz, A; Rayego-Mateos, S; Rodrigues Díez, R; Rodrigues-Díez, R; Rodríguez-Vita, J; Ruiz-Ortega, M | 1 |
| Ghilencea, L; Mario, CD; Moreno-Ambroj, C; Tyczyński, P; Witkowska, AB | 1 |
| Aguilar, C; Rodríguez-Delfín, L; Ventura, F | 1 |
| Chu, B; Dong, L; Hatsukami, T; Lane, T; Lee, C; Monick, D; Moore, A; Neradilek, MB; Phan, BA; Polissar, N; Underhill, H; Yuan, C; Zhao, XQ | 1 |
| Chuang, WL; Chuang, YH; Huang, CH; Huang, SP; Liu, CK | 1 |
| Asteriou, C; Ballas, KD; Giakoustidis, DE; Lalountas, M; Michalakis, A; Nikolaidou, C; Pavlidis, TE; Psarras, K; Sakantamis, AK; Venizelos, I | 1 |
| Ike, A; Iwata, A; Kawamura, A; Miura, S; Nishikawa, H; Saku, K; Sugihara, M; Tanaka, T | 1 |
| Li, W; Liu, K; Ma, A; Shao, L; Wang, J; Wang, Z; Wu, D; Zhang, P; Zhang, Y | 1 |
| Chu, LM; Elmadhun, NY; Feng, J; Lassaletta, AD; Liu, Y; Sellke, FW | 1 |
| Bahlmann, FH; Drexler, H; Engberding, N; Fuchs, M; Haller, H; Heineke, A; Hilfiker-Kleiner, D; Hornig, B; Kotlarz, D; Landmesser, U; Mueller, M; Schaefer, A; Spiekermann, S; Templin, C; Wiencke, A | 1 |
| Amrani, M; Chester, AH; Latif, N; Osman, L; Yacoub, MH | 1 |
| Gu, M; Liu, M; Wu, Y; Yin, C; Zhang, W; Zhu, P | 1 |
| Bezerra, DG; Lacerda Andrade, LM; Mandarim-de-Lacerda, CA; Pinto da Cruz, FO | 1 |
6 trial(s) available for atorvastatin and Fibrosis
| Article | Year |
|---|---|
Brief Report: Statin Effects on Myocardial Fibrosis Markers in People Living With HIV.
Topics: Adolescent; Adult; Amino Acids; Atorvastatin; Biomarkers; Blood Proteins; Coronary Artery Disease; Double-Blind Method; Female; Fibrosis; Galectin 3; Galectins; Growth Differentiation Factor 15; HIV; HIV Infections; Humans; Inflammation; Interleukin-1 Receptor-Like 1 Protein; Interleukin-6; Lipoproteins, LDL; Male; Middle Aged; Receptors, Interleukin-1; Young Adult | 2018 |
Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Animals; Atorvastatin; Biomarkers; Cardiomegaly; Cells, Cultured; Cholesterol; Cholesterol, LDL; Coronary Vessels; Cross-Over Studies; Cytoskeletal Proteins; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrosis; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Guanine Nucleotide Exchange Factors; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Mice; Mice, Knockout; Neuropeptides; Oxidative Stress; Phosphatidylinositol 3-Kinase; Pravastatin; Proto-Oncogene Proteins c-akt; Pyrroles; Quinolines; rac GTP-Binding Proteins; rac1 GTP-Binding Protein; RNA Interference; Signal Transduction; Transfection | 2013 |
Three-dimensional morphological response of lipid-rich coronary plaques to statin therapy: a serial optical coherence tomography study.
Topics: Aged; Algorithms; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Female; Fibrosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Lipid Metabolism; Male; Middle Aged; Plaque, Atherosclerotic; Predictive Value of Tests; Prospective Studies; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2016 |
Effects of 12 weeks of atorvastatin therapy on myocardial fibrosis and circulating fibrosis biomarkers in statin-naïve patients with hypertension with atherosclerosis.
Topics: Aged; Atherosclerosis; Atorvastatin; Biomarkers; Electrocardiography; Female; Fibrosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Myocardium | 2016 |
Is age an important factor for vascular response to statin therapy? A serial optical coherence tomography and intravascular ultrasound study.
Topics: Adolescent; Adult; Age Factors; Aged; Atorvastatin; Biomarkers; C-Reactive Protein; China; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Fibrosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Male; Middle Aged; Plaque, Atherosclerotic; Predictive Value of Tests; Rosuvastatin Calcium; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Ultrasonography, Interventional; Young Adult | 2017 |
MR imaging of carotid plaque composition during lipid-lowering therapy a prospective assessment of effect and time course.
Topics: Apolipoproteins B; Atorvastatin; Biomarkers; Calcium; Carotid Arteries; Carotid Artery Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Fibrosis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Idaho; Lipid Metabolism; Magnetic Resonance Angiography; Male; Middle Aged; Necrosis; Predictive Value of Tests; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome; Washington | 2011 |
42 other study(ies) available for atorvastatin and Fibrosis
| Article | Year |
|---|---|
Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans.
Topics: Aged; Anticoagulants; Antiviral Agents; Ascites; Atorvastatin; Carvedilol; Diuretics; Fibrosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Liver Cirrhosis; Medicare; Metformin; Paracentesis; Rifaximin; Risk Factors; United States | 2022 |
Evaluation of statins as a new therapy to alleviate chronotropic dysfunction in cirrhotic rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Atorvastatin; Cholesterol; Fibrosis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ligation; Liver; Liver Cirrhosis; Male; Malondialdehyde; Natriuretic Peptides; NF-E2-Related Factor 2; Nitric Oxide Synthase Type III; Rats; Rats, Wistar; rhoA GTP-Binding Protein; Tumor Necrosis Factor-alpha | 2022 |
Impact of atorvastatin on plasma and cardiac biomarkers of inflammation, oxidative stress, and fibrosis in a rat model of streptozotocin-induced diabetes.
Topics: Animals; Atorvastatin; Biomarkers; Diabetes Mellitus, Experimental; Fibrosis; Inflammation; Male; Nitrites; Oxidants; Oxidative Stress; Rats; Rats, Wistar; Streptozocin; Thiobarbituric Acid Reactive Substances | 2023 |
Atorvastatin-induced tolerogenic dendritic cells improve cardiac remodeling by suppressing TLR-4/NF-κB activation after myocardial infarction.
Topics: Animals; Apoptosis; Atorvastatin; Cytokines; Dendritic Cells; Disease Models, Animal; Fibrosis; Mice; Myocardial Infarction; Myocardium; Myocytes, Cardiac; NF-kappa B; Stroke Volume; Toll-Like Receptor 4; Ventricular Function, Left; Ventricular Remodeling | 2023 |
Atorvastatin reduces renal interstitial fibrosis caused by unilateral ureteral obstruction through inhibiting the transcriptional activity of YAP.
Topics: Animals; Atorvastatin; Fibrosis; Mice; Renal Insufficiency; Renal Insufficiency, Chronic; Ureteral Obstruction | 2023 |
Effects of losartan and atorvastatin on the development of early posttraumatic joint stiffness in a rat model.
Topics: Animals; Atorvastatin; Disease Models, Animal; Fibrosis; Joint Capsule; Knee Injuries; Knee Joint; Losartan; Male; Rats; Rats, Sprague-Dawley | 2019 |
Suppression of miR-143-3p contributes to the anti-fibrosis effect of atorvastatin on myocardial tissues via the modulation of Smad2 activity.
Topics: Animals; Aorta; Atorvastatin; Collagen; Constriction, Pathologic; Disease Models, Animal; Fibroblasts; Fibrosis; Gene Expression Regulation; Humans; MicroRNAs; Myocardium; Rats; Smad2 Protein; Transforming Growth Factor beta1; Ventricular Remodeling | 2020 |
Atorvastatin Reduces
Topics: Animals; Arteriovenous Shunt, Surgical; Atorvastatin; Carotid Artery, Internal; Collagen; Female; Fibrin; Fibrosis; Hemorheology; Inflammation; Jugular Veins; Macrophages; Male; Mice; Mice, Inbred C57BL; Molecular Imaging; Nanoparticles; Random Allocation; RNA, Messenger; Thrombosis; Transcription, Genetic; Vascular Access Devices; Vascular Patency | 2020 |
Inhibition of Angiotensin II-Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice.
Topics: Adiponectin; AMP-Activated Protein Kinases; Angiotensin II; Animals; Atorvastatin; Collagen Type I; Collagen Type III; Fibrosis; Gene Expression Regulation; Gene Knockout Techniques; Heart Diseases; Injections, Subcutaneous; Male; Mice; Phosphorylation; Treatment Outcome | 2017 |
Radioprotective effect of atorvastatin against ionizing radiation-induced nephrotoxicity in mice.
Topics: Animals; Apoptosis; Atorvastatin; Caspase 3; Creatinine; Disease Models, Animal; Fibrosis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Glomerulus; Lipid Peroxidation; Male; Mice; Mice, Inbred BALB C; Oxidative Stress; Radiation Protection; Radiation-Protective Agents; Radiation, Ionizing; Urea; X-Rays | 2018 |
Galectin-3 in patients with coronary heart disease and atrial fibrillation.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Atrial Fibrillation; Blood Proteins; Catheter Ablation; Coronary Disease; Female; Fibrosis; Galectin 3; Galectins; Humans; Inflammation; Male; Middle Aged; Myocardial Infarction; Severity of Illness Index; Stroke Volume | 2018 |
Atorvastatin Improves Doxorubicin-Induced Cardiac Dysfunction by Modulating Hsp70, Akt, and MAPK Signaling Pathways.
Topics: Animals; Apoptosis; Atorvastatin; Cardiotoxicity; Caspase 3; Disease Models, Animal; Doxorubicin; Fibrosis; Heart Failure; Heart Ventricles; HSP70 Heat-Shock Proteins; Male; Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats, Wistar; Signal Transduction; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Atorvastatin Prevents Myocardial Fibrosis in Spontaneous Hypertension via Interleukin-6 (IL-6)/Signal Transducer and Activator of Transcription 3 (STAT3)/Endothelin-1 (ET-1) Pathway.
Topics: Animals; Atorvastatin; Blood Pressure; Cardiomyopathies; Disease Models, Animal; Endomyocardial Fibrosis; Endothelin-1; Fibrosis; Hypertension; Interleukin-6; Male; Myocardium; Phosphorylation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; STAT3 Transcription Factor | 2019 |
Differential expression of Nad(P)H oxidase isoforms and the effects of atorvastatin on cardiac remodeling in two-kidney two-clip hypertensive rats.
Topics: Animals; Atorvastatin; Atrial Natriuretic Factor; Blotting, Western; Fibrosis; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Renovascular; Isoenzymes; Male; Membrane Glycoproteins; Myocardium; Myosin Heavy Chains; NADPH Oxidase 2; NADPH Oxidase 4; NADPH Oxidases; Pyrroles; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2013 |
Atorvastatin enhance efficacy of mesenchymal stem cells treatment for swine myocardial infarction via activation of nitric oxide synthase.
Topics: Animals; Apoptosis; Atorvastatin; C-Reactive Protein; Disease Models, Animal; Enzyme Activation; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mesenchymal Stem Cell Transplantation; Myocardial Infarction; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pyrroles; Swine; Tomography, Emission-Computed, Single-Photon; Ventricular Function, Left | 2013 |
Atorvastatin reduces myocardial fibrosis in a rat model with post-myocardial infarction heart failure by increasing the matrix metalloproteinase-2/tissue matrix metalloproteinase inhibitor-2 ratio.
Topics: Animals; Atorvastatin; Collagen; Disease Models, Animal; Female; Fibrosis; Heart Failure; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 2; Myocardial Infarction; Myocardium; Pyrroles; Rats; Rats, Wistar; Tissue Inhibitor of Metalloproteinase-2; Ventricular Remodeling | 2013 |
Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart failure model rats.
Topics: Animals; Atorvastatin; Cells, Cultured; Disease Models, Animal; Fibroblasts; Fibrosis; Heart Failure, Diastolic; Heptanoic Acids; HSP47 Heat-Shock Proteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Myocardium; Pyrroles; Rats; Rats, Inbred Dahl; rho-Associated Kinases; Ventricular Function, Left | 2014 |
High-dose atorvastatin ameliorates the uterine microenvironment in streptozotocin-induced diabetic rats.
Topics: Animals; Atorvastatin; Diabetes Mellitus, Experimental; Endometrium; ErbB Receptors; Female; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Rats; Rats, Sprague-Dawley; Uterus; Vascular Endothelial Growth Factor A | 2014 |
Effect of angiotensin II and small GTPase Ras signaling pathway inhibition on early renal changes in a murine model of obstructive nephropathy.
Topics: Angiotensin II; Animals; Atorvastatin; Disease Models, Animal; Fibrosis; Heptanoic Acids; Humans; Kidney; Kidney Diseases; Mice; Monomeric GTP-Binding Proteins; Pyrroles; Receptor, Angiotensin, Type 1; Signal Transduction; Ureteral Obstruction | 2014 |
MicroRNA-208a Increases Myocardial Endoglin Expression and Myocardial Fibrosis in Acute Myocardial Infarction.
Topics: Animals; Atorvastatin; Blotting, Western; Cells, Cultured; Disease Models, Animal; Endoglin; Fibrosis; Gene Expression Regulation; Hemodynamics; Heptanoic Acids; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Male; MicroRNAs; Muscle Cells; Myocardial Infarction; Polymerase Chain Reaction; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Sensitivity and Specificity; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2015 |
Treatment with atorvastatin attenuates progression of insulin resistance and pancreatic fibrosis in the Otsuka Long-Evans Tokushima fatty rats.
Topics: Animals; Antioxidants; Apoptosis; Atorvastatin; Body Weight; Eating; Fibrosis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Male; Oxidative Stress; Pancreas; Rats; Rats, Inbred OLETF; Transforming Growth Factor beta1 | 2016 |
Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.
Topics: Atorvastatin; Carcinoma, Hepatocellular; Cohort Studies; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fibrosis; Fluvastatin; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged | 2016 |
Atorvastatin prevents advanced glycation end products (AGEs)-induced cardiac fibrosis via activating peroxisome proliferator-activated receptor gamma (PPAR-γ).
Topics: Actins; Anilides; Animals; Atorvastatin; Cell Proliferation; Cells, Cultured; Down-Regulation; Fibrosis; Glycation End Products, Advanced; Heart Diseases; Heart Function Tests; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; MAP Kinase Signaling System; PPAR gamma; Rats; Rats, Sprague-Dawley; Receptor for Advanced Glycation End Products; Ultrasonography | 2016 |
Atorvastatin Improves Ventricular Remodeling after Myocardial Infarction by Interfering with Collagen Metabolism.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Catheter Ablation; Collagen; Disease Models, Animal; Fibrosis; Gene Expression; Heart Ventricles; Hemodynamics; Interleukin-1; Male; Matrix Metalloproteinase 1; Myocardial Infarction; Myocardium; NF-kappa B p50 Subunit; Rats; Rats, Wistar; Tissue Inhibitor of Metalloproteinase-1; Ventricular Remodeling | 2016 |
Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways.
Topics: Angiotensin II; Atorvastatin; Cell Line; Cell Transdifferentiation; Connective Tissue Growth Factor; Epithelial Cells; Fibrosis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Kidney Tubules, Proximal; Mitogen-Activated Protein Kinase Kinases; Phenotype; Protein Kinase Inhibitors; Pyrroles; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Simvastatin; Time Factors; Transfection | 2008 |
Regression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysis.
Topics: Aged; Atorvastatin; Calcinosis; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Female; Fibrosis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Necrosis; Pilot Projects; Pioglitazone; Prospective Studies; Pyrroles; Registries; Thiazolidinediones; Time Factors; Treatment Outcome; Ultrasonography, Interventional; User-Computer Interface | 2009 |
Effect of atorvastatin on cardiac remodelling and mortality in rats following hyperglycemia and myocardial infarction.
Topics: Animals; Atorvastatin; Body Weight; Cardiac Volume; Collagen Type I; Collagen Type III; Diabetes Mellitus, Experimental; Disease Models, Animal; Female; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Myocardial Infarction; Myocardium; Pyrroles; Rats; Rats, Sprague-Dawley; Ventricular Remodeling | 2010 |
Additive beneficial effects of amlodipine and atorvastatin in reversing advanced cardiac hypertrophy in elderly spontaneously hypertensive rats.
Topics: Aging; Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiomegaly; Drug Synergism; Drug Therapy, Combination; Fibrosis; Heart Failure, Diastolic; Hemodynamics; Heptanoic Acids; Myocytes, Cardiac; NADPH Oxidases; Natriuretic Peptide, Brain; Oxidative Stress; Pyrroles; Random Allocation; Rats; Rats, Inbred SHR; Reactive Oxygen Species; Superoxide Dismutase; Ventricular Dysfunction, Left | 2009 |
Atorvastatin reverses cardiac remodeling possibly through regulation of protein kinase D/myocyte enhancer factor 2D activation in spontaneously hypertensive rats.
Topics: Animals; Atorvastatin; Blood Pressure; Disease Models, Animal; Enzyme Activation; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxyproline; Hypertension; Hypertrophy, Left Ventricular; Lipids; Male; MEF2 Transcription Factors; Myocardium; Protein Kinase C; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; Time Factors; Transcription Factors; Ventricular Remodeling | 2010 |
Atorvastatin ameliorates tubulointerstitial fibrosis and protects renal function in chronic partial ureteral obstruction cases.
Topics: Animals; Atorvastatin; Chronic Disease; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Tubules; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Ureteral Obstruction | 2009 |
Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-β-independent process.
Topics: Angiotensin II; Animals; Aorta; Atorvastatin; Blotting, Western; Cells, Cultured; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyrroles; Rats; Rats, Wistar; Signal Transduction; Simvastatin; Smad Proteins; Transforming Growth Factor beta; Vasoconstrictor Agents | 2010 |
Long term observation of thin-cap fibroatheroma by optical coherence tomography.
Topics: Atorvastatin; Coronary Artery Disease; Coronary Vessels; Fibrosis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Necrosis; Pyrroles; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2010 |
[Atorvastatin induced increase in homologous angiotensin I converting enzyme (ACE2) mRNA is associated to decreased fibrosis and decreased left ventricular hypertrophy in a rat model of diabetic cardiomyopathy].
Topics: Animals; Atorvastatin; Diabetic Cardiomyopathies; Disease Models, Animal; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Male; Peptidyl-Dipeptidase A; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2011 |
Atorvastatin ameliorates tissue damage of obstructed ureter in rats.
Topics: Animals; Apoptosis; Atorvastatin; Cytokines; Female; Fibrosis; Heptanoic Acids; Hydronephrosis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; In Situ Nick-End Labeling; Muscle, Smooth; Proliferating Cell Nuclear Antigen; Pyrroles; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta1; Ureter; Ureteral Obstruction | 2011 |
Postoperative adhesion prevention using a statin-containing cellulose film in an experimental model.
Topics: Animals; Atorvastatin; Biocompatible Materials; Carboxymethylcellulose Sodium; Fibrosis; Heptanoic Acids; Hyaluronic Acid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Random Allocation; Rats; Rats, Wistar; Tissue Adhesions | 2012 |
Plasma pentraxin-3 levels are associated with coronary plaque vulnerability and are decreased by statin.
Topics: Aged; Angina, Stable; Atorvastatin; Biomarkers; C-Reactive Protein; Case-Control Studies; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Down-Regulation; Female; Fibrosis; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Predictive Value of Tests; Pyrroles; Serum Amyloid P-Component; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Uric Acid | 2012 |
Atorvastatin preconditioning improves the forward blood flow in the no-reflow rats.
Topics: Animals; Atorvastatin; Echocardiography; Fibrinogen; Fibrosis; Hemodynamics; Heptanoic Acids; Inflammation; Male; Microcirculation; Myocardial Reperfusion Injury; Myocardium; Myocytes, Cardiac; Pyrroles; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Tumor Necrosis Factor-alpha | 2014 |
Atorvastatin increases oxidative stress and modulates angiogenesis in Ossabaw swine with the metabolic syndrome.
Topics: Angiogenesis Inducing Agents; Angiogenic Proteins; Animals; Atorvastatin; Biomarkers; Collateral Circulation; Coronary Circulation; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Metabolic Syndrome; Microvessels; Myocardial Ischemia; Myocardial Perfusion Imaging; Myocardium; Neovascularization, Physiologic; Oxidative Stress; Pyrroles; Signal Transduction; Swine; Swine, Miniature; Vasodilation; Vasodilator Agents | 2012 |
Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase.
Topics: Animals; Atorvastatin; Biological Availability; Capillaries; Cells, Cultured; Collateral Circulation; Drug Resistance; Endothelial Cells; Fibrosis; Heart Failure; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pyrroles; Random Allocation; Ultrasonography; Vasodilation; Ventricular Function, Left; Ventricular Remodeling | 2004 |
Role of human valve interstitial cells in valve calcification and their response to atorvastatin.
Topics: Aged; Alkaline Phosphatase; Aortic Valve; Aortic Valve Stenosis; Atorvastatin; Bone Morphogenetic Protein 2; Bone Morphogenetic Protein 4; Bone Morphogenetic Protein 7; Bone Morphogenetic Proteins; Calcinosis; Cell Differentiation; Cells, Cultured; Connective Tissue Cells; Culture Media; Fibrosis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Osteoblasts; Osteocalcin; Pyrroles; Transforming Growth Factor beta; Transforming Growth Factor beta1; Transforming Growth Factor beta3 | 2006 |
Protective effects of atorvastatin on chronic allograft nephropathy in rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Chemokines; Chronic Disease; Cyclosporine; Cytokines; Drug Therapy, Combination; Extracellular Matrix Proteins; Fibrosis; Gene Expression; Graft Rejection; Heptanoic Acids; Immunosuppressive Agents; Kidney Transplantation; Male; Monocytes; Proteinuria; Pyrroles; Rats; Rats, Inbred F344; Rats, Inbred Lew; T-Lymphocytes; Transplantation, Homologous | 2007 |
Atorvastatin attenuates cardiomyocyte loss in adult rats from protein-restricted dams.
Topics: Animals; Atorvastatin; Blood Pressure; Body Mass Index; Cardiomegaly; Diet, Protein-Restricted; Fibrosis; Heptanoic Acids; Hypertrophy, Left Ventricular; Male; Myocardial Reperfusion; Myocytes, Cardiac; Perfusion; Pyrroles; Rats; Rats, Wistar | 2008 |